Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Short Interest Update

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) was the recipient of a significant drop in short interest in the month of March. As of March 15th, there was short interest totalling 2,850,000 shares, a drop of 24.8% from the February 28th total of 3,790,000 shares. Currently, 11.7% of the shares of the company are sold short. Based on an average daily volume of 1,830,000 shares, the short-interest ratio is presently 1.6 days.

Hedge Funds Weigh In On Reviva Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Tang Capital Management LLC acquired a new position in shares of Reviva Pharmaceuticals in the fourth quarter worth $308,000. Ameriprise Financial Inc. bought a new stake in shares of Reviva Pharmaceuticals during the 4th quarter worth $84,000. Geode Capital Management LLC raised its holdings in Reviva Pharmaceuticals by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 278,496 shares of the company’s stock worth $401,000 after acquiring an additional 42,376 shares during the period. EMC Capital Management lifted its position in shares of Reviva Pharmaceuticals by 142.0% during the 4th quarter. EMC Capital Management now owns 44,535 shares of the company’s stock worth $81,000 after purchasing an additional 26,134 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of Reviva Pharmaceuticals in the fourth quarter valued at approximately $45,000. Hedge funds and other institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Price Performance

Shares of Reviva Pharmaceuticals stock traded down $0.33 on Tuesday, hitting $0.62. The company had a trading volume of 5,424,407 shares, compared to its average volume of 1,084,367. Reviva Pharmaceuticals has a 52 week low of $0.55 and a 52 week high of $4.28. The company has a market cap of $20.76 million, a PE ratio of -0.56 and a beta of -0.09. The business has a 50-day simple moving average of $1.51 and a 200-day simple moving average of $1.47.

Reviva Pharmaceuticals (NASDAQ:RVPH) last issued its quarterly earnings results on Monday, March 31st. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. On average, equities research analysts predict that Reviva Pharmaceuticals will post -0.97 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Roth Capital raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 10th. D. Boral Capital decreased their price target on shares of Reviva Pharmaceuticals from $15.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday. Roth Mkm assumed coverage on shares of Reviva Pharmaceuticals in a report on Friday, January 10th. They issued a “buy” rating and a $7.00 price target on the stock. HC Wainwright lowered their target price on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, January 22nd. Finally, Maxim Group raised shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a research note on Friday, January 10th. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Reviva Pharmaceuticals presently has an average rating of “Buy” and an average target price of $10.00.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.